他汀治疗动脉粥样硬化无应答的临床与冠脉斑块预测因素
多中心PARADIGM注册研究纳入649例基线及随访冠脉CTA间隔≥2年的他汀治疗患者,31.5%出现动脉粥样硬化他汀无应答(PAV年增长≥1.0%)。糖尿病、高危斑块特征数量、非钙化及钙化PAV是独立预测因素;次要终点仅非钙化PAV和高危斑块特征数量为独立决定因素。
要点
- 基线斑块负荷和高危斑块特征可预测他汀治疗下的斑块进展。
- 糖尿病、高危斑块特征数量、非钙化及钙化PAV与无应答独立相关。
- 斑块负荷最高且含高危特征者进展风险最高,或需额外治疗。
关键影像表现/征象
- 无应答组与应答组在年龄、糖尿病、高血压及基线所有斑块特征(高危斑块特征、钙化及非钙化PAV、管腔体积)上差异显著。
- 仅糖尿病、高危斑块特征数量、非钙化PAV和钙化PAV与无应答独立相关(OR分别为1.41、1.15、1.06、1.07)。
- 次要终点(N=125,19.2%)仅非钙化PAV和高危斑块特征数量为独立决定因素(OR分别为1.08和1.21)。
诊断标准与关键数值
- 动脉粥样硬化他汀无应答定义为PAV每年绝对增加≥1.0%。
- 次要终点需额外满足低衰减斑块或纤维脂肪斑块进展。
- 无应答独立相关OR:糖尿病1.41(95%CI 0.95-2.11)、高危斑块特征数量1.15(95%CI 1.09-1.21)、非钙化PAV 1.06(95%CI 1.02-1.10)、钙化PAV 1.07(95%CI 1.03-1.12)。
- 次要终点独立决定因素OR:非钙化PAV 1.08(95%CI 1.03-1.13)、高危斑块特征数量1.21(95%CI 1.06-1.21)。
临床应用与阅片要点
- 阅片时应在报告中描述高危斑块特征数量及非钙化/钙化PAV,以提示他汀无应答风险。
- 对糖尿病合并高斑块负荷及高危斑块特征者,可提示临床考虑额外风险降低治疗。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Statins reduce the incidence of major cardiovascular events, but residual risk remains. The study examined the determinants of atherosclerotic statin nonresponse.
OBJECTIVES: This study aimed to investigate factors associated with statin nonresponse-defined atherosclerosis progression in patients treated with statins.
METHODS: The multicenter PARADIGM (Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging) registry included patients who underwent serial coronary computed tomography angiography ≥2 years apart, with whole-heart coronary tree quantification of vessel, lumen, and plaque, and matching of baseline and follow-up coronary segments and lesions. Patients with statin use at baseline and follow-up coronary computed tomography angiography were included. Atherosclerotic statin nonresponse was defined as an absolute increase in percent atheroma volume (PAV) of 1.0% or more per year. Furthermore, a secondary endpoint was defined by the additional requirement of progression of low-attenuation plaque or fibro-fatty plaque.
RESULTS: The authors included 649 patients (age 62.0 ± 9.0 years, 63.5% male) on statin therapy and 205 (31.5%) experienced atherosclerotic statin nonresponse. Age, diabetes, hypertension, and all atherosclerotic plaque features measured at baseline scan (high-risk plaque [HRP] features, calcified and noncalcified PAV, and lumen volume) were significantly different between patients with and without atherosclerotic statin nonresponse, whereas only diabetes, number of HRP features, and noncalcified and calcified PAV were independently associated with atherosclerotic statin nonresponse (odds ratio [OR]: 1.41 [95% CI: 0.95-2.11], OR: 1.15 [95% CI: 1.09-1.21], OR: 1.06 [95% CI: 1.02-1.10], OR: 1.07 [95% CI: 1.03-1.12], respectively). For the secondary endpoint (N = 125, 19.2%), only noncalcified PAV and number of HRP features were the independent determinants (OR: 1.08 [95% CI: 1.03-1.13] and OR: 1.21 [95% CI: 1.06-1.21], respectively).
CONCLUSIONS: In patients treated with statins, baseline plaque characterization by plaque burden and HRP is associated with atherosclerotic statin nonresponse. Patients with the highest plaque burden including HRP were at highest risk for plaque progression, despite statin therapy. These patients may need additional therapies for further risk reduction.
引用
- van Rosendael, van den Hoogen, Lin, et al. Clinical and Coronary Plaque Predictors of Atherosclerotic Nonresponse to Statin Therapy. JACC Cardiovasc Imaging. 2022. PMID: 36648046. doi:10.1016/j.jcmg.2022.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。